India, Nov. 25 -- Eris Lifesciences on Tuesday announced that its board has approved the acquisition of the remaining 30% stake in its subsidiary Swiss Parenterals.
The transaction will be executed through a share swap, involving a preferential allotment of Eris shares to seller Naishadh Shah, who will join the company's leadership as a shareholder with long-term strategic alignment, the company said.
Welcoming him, Amit Bakshi, Chairman and Managing Director of Eris Lifesciences, said, "We are delighted to welcome Naishadh Shah to the community of Erisians. We also intend to appoint him as the Managing Director of Swiss Parenterals."
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....